Igor Stojkovski - Academia.edu (original) (raw)

Uploads

Papers by Igor Stojkovski

European Journal of Cancer

Radiology and oncology, 2017

The aim of the study was to analyze impact of irradiated brain volume V57 Gy (volume receiving 57... more The aim of the study was to analyze impact of irradiated brain volume V57 Gy (volume receiving 57 Gy and more) on time to progression and survival of patients with glioblastoma. Dosimetric analysis of treatment plan data has been performed on 70 patients with glioblastoma, treated with postoperative radiochemotherapy with temozolomide, followed by adjuvant temozolomide. Patients were treated with 2 different methods of definition of treatment volumes and prescription of radiation dose. First group of patients has been treated with one treatment volume receiving 60 Gy in 2 Gy daily fraction (31 patients) and second group of the patients has been treated with "cone-down" technique, which consisted of two phases of treatment: the first phase of 46 Gy in 2 Gy fraction followed by "cone-down" boost of 14 Gy in 2 Gy fraction (39 patients). Quantification of V57 Gy and ratio brain volume/V57Gy has been done. Average values of both parameters have been taken as a thresho...

Open access Macedonian journal of medical sciences, Jan 15, 2017

The primary objective of the study was to evaluate the overall survival of women with advanced st... more The primary objective of the study was to evaluate the overall survival of women with advanced stage (Stage IIIA-IV) high-grade serous ovarian cancer in Macedonia. The study was a cross-sectional medical record review of patients diagnosed with advanced stage HGSC. Patients were deemed eligible for inclusion if they were diagnosed with an advanced stage (Stage IIIA-IV) HGSC of the ovary, fallopian tube or peritoneum between 2009 and 2015. The data were analyzed in a descriptive fashion and summary statistics were provided, as appropriate. Survival was calculated using the Kaplan-Meier method. A total of 81 eligible patients were identified and included in the study. The average overall survival in the studied cohort was 46.59 months (95%CI = 39.11-54.06). Patients that were optimally debulked and patients that had a platinum-free interval larger than 12 months had significantly longer survival in the current series (p < 0.001). the average overall survival of advanced stage HGSC ...

Prilozi / Makedonska akademija na naukite i umetnostite, Oddelenie za biološki i medicinski nauki = Contributions / Macedonian Academy of Sciences and Arts, Section of Biological and Medical Sciences, 2008

The aim of the study was to investigate the efficacy of concurrent chemoradiotherapy (CCRT) in pa... more The aim of the study was to investigate the efficacy of concurrent chemoradiotherapy (CCRT) in patients with locally and/or regionally advanced nasopharyngeal carcinoma (NPC). Between February 2005 and November 2007, 27 patients with advanced NPC were included in a prospective study of CCRT at the Radiotherapy and Oncology Institute in Skopje. Radiotherapy was performed using a sophisticated three-dimensional conformal technique. A dose of 69.4-71.4 Gy (median, 69.4 Gy) was delivered to the primary tumour and to the positive neck nodes. Chemotherapy consisted of cisplatin 30 mg/m(2) given concomitantly with radiation on a weekly basis. The median age was 49 years and 51.2% had stage IV disease. Eighty-eight percent received >or= 5 cycles of concurrent cisplatin. Complete response rates three months after chemoradiotherapy completion were 81.5% (22 of 27) and 91.3% (21 of 23) at the primary site and in the neck, respectively. Only one patient had a locoregional relapse and four pa...

European Journal of Cancer Supplements, 2003

Radiation Oncology, 2012

Background Concurrent radiochemotherapy is a recommended treatment option for patients with local... more Background Concurrent radiochemotherapy is a recommended treatment option for patients with locally advanced squamous cell head and neck carcinomas with recent data showing the most significant absolute overall and event-free survival benefit achieved in patients with oropharyngeal tumours. The aim of this study was to analyse the results of three-dimensional conformal radiotherapy given with concomitant weekly cisplatin in patients with advanced oropharyngeal carcinoma and to identify prognostic factors influencing outcomes of this patients category. Methods Sixty-five patients with stage III or IV squamous cell carcinoma of the oropharynx who underwent concurrent radiochemotherapy between January 2005 and December 2010 were retrospectively analyzed. All patients received radiotherapy to 70 Gy/35 fractions/2 Gy per fraction/5 fractions per week. Concurrent chemotherapy consisted of weekly cisplatin (30 mg/m2) started at the first day of radiotherapy. Results Median age was 57 years...

Journal of Surgical Oncology, 1997

Purpose: The aim of this study was to evaluate different prognostic factors affecting response to... more Purpose: The aim of this study was to evaluate different prognostic factors affecting response to treatment, locoregional control (LRC) and survival in patients with advanced hypopharyngeal squamous cell carcinoma (HPSCC). Methods: A retrospective analysis of 41 patients with advanced HPSCC who had undergone definitive concurrent chemoradiation treatment between January 2006 and October 2009 was performed. Results: Complete composite response (CCR) was achieved in 27 patients (65.9%). Significant prognostic factors for CCR were T stage, technique of radiation, and gross tumor volume (GTV). Unfavorable prognostic factors for CCR in multivariate analysis were higher T stage and radiation technique with electron-photon fields. The 2-year LRC rate was 51.3%. The 2-year disease-free survival (DFS) and overall survival (OS) rates were 29.3% and 32.8%, respectively. Significant prognostic factors for LRC, DFS, and OS in univariate analysis were T stage, overall stage, and GTV. OS was also significantly influenced by N stage. In multivariate analysis T stage was found to be the only significant independent prognostic factor for LRC (p=0.003), DFS (p=0.01), and OS (p=0.005). Conclusion: Revealing the significant prognostic value of T stage for CCR, LRC, DFS, and OS in the multivariate analysis, we consider that the implementation of intensitymodulated radiotherapy (IMRT) and the adoption of intensified concurrent chemoradiotherapy (CCRT), sequential therapy, and targeted therapy should be strongly advocated in order to improve outcome in patients with locally advanced HPSCC.

Expert Review of Anticancer Therapy, 2008

... David Hoopes and Robert D Timmerman Author for correspondence Ohio State University Medical ... more ... David Hoopes and Robert D Timmerman Author for correspondence Ohio State University Medical Center, Department of Radiation Medicine, Arthur G James ... To facilitate accuracy of thesetup and treatment delivery, it is important that the patient remains comfortable in the ...

$Research paper thumbnail of 8034 POSTER Capecitabine as Second- and Third-line Chemotherapy in the Treatment of Platinum-refractory Epithelial Ovarian Cancer$

European Journal of Cancer, 2011

ABSTRACT Background: The aim of the study was to evaluate the value of Capecitabine (Xelode) in t... more ABSTRACT Background: The aim of the study was to evaluate the value of Capecitabine (Xelode) in treatment of epithelial ovarian cancer, after failure of initial chemotherapy. Response rates to first-line chemotherapy in women with ovarian cancer are high but most patients relapse and need further treatment. Recurrent disease is incurable, however, many patients can obtain good palliation from further treatment. Material and Method: The study included 20 patients with epithelial ovarian cancer treated initially with cytoreductive surgery and followed by chemotherapy treatment: 14 patients received platinum/paclitaxel therapy and 6 patients received platinum/cyclophosphamide therapy. Progression of disease was manifested with hepatic metastases in 11 patients (55%), lung metastases in 2 (10%) and an increase in serum CA125 in 5 patients (25%). Comparison of the value of serum CA125 before and after treatment was taken as an indicator of response to chemotherapy. The treatment schedule consisted of oral capecitabine 1250mg/m2 administrated twice daily for 14 days, followed by 7-day rest period. Treatment was administrated orally within 30 min of breakfast and dinner, and swallowed with approximately 200ml of water. The cycle was repeated every 21 days. Results: 18 patients (80%) received 6 courses chemotherapy with Capecitabine, 4 (20%) did not achieve the planned 6 courses of chemotherapy due to deterioration of their general condition. In 10 patients (50%) deceased value of CA125 was observed, in 8 (40%) value was unchanged, and in 2 (10%) an increase of serum CA125 was noted. All patients were evaluable for safety. Capecitabine was very well tolerated, with the most common clinical adverse events being nausea and diarrhoea, neither of which occurred with grade 3 or 4 intensity. Conclusions: Capecitabine has demonstrated promising activity and a favorable safety profile in the treatment of platinum-refractory epithelial ovarian cancer. The safety and convenience advantages afforded to patients over current i.v. options make capecitabine an ideal agent for administration in the outpatient setting, potentially freeing them from the burden of i.v. therapy.

British Journal of Surgery, 1997

Background There is controversy whether adjuvant radiotherapy should be given before or after sur... more Background There is controversy whether adjuvant radiotherapy should be given before or after surgery for locally advanced, resectable rectal cancer. Preoperative radiotherapy substantially reduces local recurrence rates but may increase postoperative complications. In addition, patients found to have early cancers are treated unnecessarily. This study is a randomized trial of postoperative radiotherapy in patients who had a potentially curative resection for locally advanced rectal carcinoma. Methods Following complete excision of a Dukes B or C rectal cancer, 172 patients were randomized to adjuvant radiotherapy (46 Gy 5 days per week in 30-38 days) (84 patients) or controls (88 patients). Results After a median follow-up of 85 months, no benefit from postoperative radiotherapy had been observed in disease-free survival (P = 041), overall survival (P = 052), local recurrence-free interval (P = 0.46) or in the number and sites of recurrence. Acute toxicity following radiotherapy included diarrhoea (20 per cent), cystitis (13 per cent), delayed wound healing (7 per cent), pneumonia (5 per cent) and seizures (1 per cent). Late complications included reoperation for small bowel obstruction (5 per cent), chronic diarrhoea (20 per cent), chronic cystitis (12 per cent) and persistent perineal sinus (9 per cent). In the group who had surgery alone, late morbidity was found in 11 per cent. Conclusion This trial failed to demonstrate any improvement in overall survival or local control when postoperative irradiation was given following resection of locally advanced rectal carcinoma.

Archive of oncology, 2010

Background: Purpose of this study was to determine patterns of failure in young adults with head ... more Background: Purpose of this study was to determine patterns of failure in young adults with head and neck cancer treated with 3-D conformal radiotherapy. Methods: Twenty-eight patients with head and neck cancer younger than 41 years of age were treated with 3-D conformal radiotherapy. Patients? median age was 31.4 years. Radiotherapy was delivered in the median total dose of 67.2 Gy to PTV (range, 60.0-70.0 Gy) with or without concurrent cisplatin. Results: The median duration of follow-up was 20 months. Distant metastases were the most frequent pattern of failure. The locoregional relapse-free survival (LRR-FS) rate at 2 years was 66.6%. The median duration of LRR-FS was 15 months. The distant metastases relapse-free survival (DMR-FS) rate at 2 years was 65.7%. The median duration of DMR-FS was also 15 months. The overall survival (OS) rate at 2 years was 57.2%. The median duration of OS was 20 months. Conclusion: Radiotherapy with or without concurrent chemotherapy plays an import...